indazoles has been researched along with idelalisib in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Burke, RT; Clarke, AS; Currie, KS; Dipaolo, JA; Druker, BJ; Lannutti, BJ; Loriaux, MM; Maciejewski, P; Meadows, S; Mitchell, SA; Spurgeon, SE | 1 |
| Abella-Dominicis, E; Barr, PM; Cheson, BD; Di Paolo, J; Dreiling, LK; Friedberg, JW; Greenwald, DR; Hawkins, MJ; He, J; Hu, J; Joshi, A; Lee, H; Liem, AK; Mclntyre, RE; O'Brien, SM; Reddy, A; Saylors, GB; Spurgeon, SE | 1 |
| Maslen, SL; Masson, GR; Williams, RL | 1 |
| Bhutkar, A; Chen, PY; Chung, KM; Dorans, KJ; Hong, E; Jacks, T; Muzumdar, MD; Noll, EM; Sprick, MR; Trumpp, A | 1 |
| Akritidou, MA; Anagnostopoulos, A; Belloni, D; Chartomatsidou, E; Ferrero, E; Ghia, P; Kotta, K; Ntoufa, S; Papakonstantinou, N; Rosenquist, R; Rovida, A; Stamatopoulos, K; Stavroyianni, N; Trangas, T | 1 |
| Bhargava, P; Danilov, AV; Dyer, MJS; Fegan, CD; Herbaux, C; Hillmen, P; Huang, X; Humeniuk, R; Jürgensmeier, JM; Karlin, L; Kio, EA; Mitra, SS; Rule, SA; Walter, HS; Yi, PC; Zhou, Z | 1 |
| Bhargava, P; Bouabdallah, K; Cartron, G; Danilov, AV; Davies, AJ; Dyer, MJS; Fegan, C; Hodson, DJ; Huang, X; Humeniuk, R; Jürgensmeier, JM; Li, B; Morschhauser, F; Radford, J; Rajakumaraswamy, N; Rule, SA; Salles, G; Spurgeon, S; Walter, HS; Ysebaert, L | 1 |
3 trial(s) available for indazoles and idelalisib
| Article | Year |
|---|---|
Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Class I Phosphatidylinositol 3-Kinases; Cytokines; Early Termination of Clinical Trials; Female; Humans; Indazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Proteins; Pneumonia; Protein Kinase Inhibitors; Purines; Pyrazines; Quinazolinones; Salvage Therapy; Syk Kinase | 2016 |
Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Imidazoles; Indazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Purines; Pyrazines; Pyrimidines; Quinazolinones; Salvage Therapy; Tissue Distribution | 2020 |
Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Imidazoles; Indazoles; Lymphoma, B-Cell; Male; Middle Aged; Protein Kinase Inhibitors; Purines; Pyrazines; Pyrimidines; Quinazolinones | 2021 |
4 other study(ies) available for indazoles and idelalisib
| Article | Year |
|---|---|
A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Drug Synergism; Humans; Indazoles; Intracellular Signaling Peptides and Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Purines; Pyrazines; Quinazolinones; Signal Transduction; Syk Kinase | 2014 |
Analysis of phosphoinositide 3-kinase inhibitors by bottom-up electron-transfer dissociation hydrogen/deuterium exchange mass spectrometry.
Topics: Antineoplastic Agents; Binding Sites; Class I Phosphatidylinositol 3-Kinases; Class Ia Phosphatidylinositol 3-Kinase; Deuterium Exchange Measurement; Drug Evaluation, Preclinical; Electron Transport; Enzyme Inhibitors; Humans; Indazoles; Models, Molecular; Molecular Weight; Oligonucleotides; Peptide Fragments; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Conformation; Purines; Pyridazines; Quinazolinones; Quinolines; Recombinant Fusion Proteins; Reproducibility of Results; Signal Processing, Computer-Assisted; Sulfonamides; Tandem Mass Spectrometry; Triazines | 2017 |
Survival of pancreatic cancer cells lacking KRAS function.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Carcinoma, Pancreatic Ductal; DNA Copy Number Variations; Humans; Immunoblotting; Indazoles; Mice; Morpholines; Pancreatic Neoplasms; Phenylurea Compounds; Piperidines; Proto-Oncogene Mas; Proto-Oncogene Proteins p21(ras); Purines; Pyrimidines; Pyrimidinones; Quinazolinones; Sulfonamides; Thiazoles | 2017 |
Inhibition of EZH2 and immune signaling exerts synergistic antitumor effects in chronic lymphocytic leukemia.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; B-Lymphocytes; Bridged Bicyclo Compounds, Heterocyclic; Down-Regulation; Drug Synergism; Enhancer of Zeste Homolog 2 Protein; Enzyme Inhibitors; Histones; Humans; Indazoles; Indoles; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Purines; Pyrazoles; Pyridones; Pyrimidines; Quinazolinones; Signal Transduction; Sulfonamides; Tumor Microenvironment | 2019 |